NPM1 and triple-negative breast carcinoma: APE1 and its regulatory factor NPM1 could also reduce the cytotoxicity of platinum-based chemotherapy drugs to triple-negative breast cancer cells, and reduced levels of APE1 in breast cancer cells could improve its sensitivity to olapalil [27].